GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) shares dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $2.34 and last traded at $2.34. Approximately 2,091 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 580,263 shares. The stock had previously closed at $2.38.
GT Biopharma Trading Down 1.7 %
The company has a market cap of $5.93 million, a P/E ratio of -0.33 and a beta of 1.48. The company has a 50 day moving average price of $2.34 and a 200-day moving average price of $2.54.
GT Biopharma Company Profile
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Further Reading
- Five stocks we like better than GT Biopharma
- Where Do I Find 52-Week Highs and Lows?
- IBM’s AI Offensive: Assessing IBM’s Path to Renewed Growth
- Growth Stocks: What They Are, Examples and How to Invest
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Pros And Cons Of Monthly Dividend Stocks
- Is Energy Transfer Undervalued or a Value Trap?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
